Browse Trials
Find Breast Cancer Clinical Trials That Are Right For You
The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.
Use the search box and filters to find a trial that’s right for you.
Currently viewing trials
(Last updated: September 12, 2024)
Close
Treatment
Brain Mets
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Leptomeningeal Disease
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: ADC
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Non-Treatment
Activities
Complementary and Integrative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Healthy/High Risk
Imaging
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Support/Education
Surveys/Interviews/Registries
Close
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
dMMR/MSI-H
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
Click here to view online studies and trials that do not require site visits
1
NEAREST SITE: 3 miles
University of California San Francisco
San Francisco,CA
VISITS: 2 visits
PHASE: II
NCT ID: NCT04821141
Bazedoxifene and Estrogen Hormone Therapy to Reduce Risk Factors for Developing Breast Cancer
Randomized IIB Study of the Effect of Bazedoxifene Plus Conjugated Estrogens on Breast Imaging and Tissue Biomarkers in Peri or Post-Menopausal Women at Increased Risk for Development of Breast Cancer Scientific Title
Purpose
To study whether bazedoxifene and estrogen affect risk factors associated with developing breast cancer.
Who is this for?
Perimenopausal and postmenopausal women ages 45 to 60 who experience hot flashes and/or night sweats at least once a week and have a moderate risk of developing breast cancer. Risk factors include a family history of breast cancer, prior breast biopsies, or one of the following gene mutations: ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53, PTEN. You must not have a BRCA1/2 mutation.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bazedoxifene, by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Estrogen, by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Fine needle aspiration biopsy, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mammogram, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Fine needle aspiration biopsy, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> </ul> <p class="seamTextPara"> followed 6 months later by (optional): </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bazedoxifene, by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Estrogen, by mouth, daily for 6 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bazedoxifene is a type of hormone therapy called a selective estrogen receptor modulator (SERM). SERMs work by blocking the activity of estrogen. It may help reduce the risk of breast cancer.</li> <li class="seamTextUnorderedListItem">Estrogen is a hormone used to treat women experiencing hot flashes.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04821141' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-03864&r=1#:~:text=Giving%20bazedoxifene%20with%20conjugated%20estrogens,increased%20risk%20for%20breast%20cancer.' target='_blank'>National Cancer Institute: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a614004.html' target='_blank'>Medline Plus: Bazedoxifene and Estrogen</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/cancer/breast/basic_info/mammograms.htm' target='_blank'>Centers for Disease Control and Prevention: Mammogram</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-biopsy/fine-needle-aspiration-biopsy-of-the-breast.html#:~:text=During%20a%20fine%20needle%20aspiration,needle%20biopsy%20is%20often%20preferred).' target='_blank'>American Cancer Society: Fine Needle Aspiration Biopsy</a> </li></ul>
2
NEAREST SITE: 348 miles
USC / Norris Comprehensive Cancer Center
Los Angeles,CA
VISITS: 1 visit every 6 months for 5 years
PHASE: III
NCT ID: NCT04711109
Denosumab to Prevent Breast Cancer in Women With an Inherited BRCA1 Mutation
BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation Scientific Title
Purpose
To study the safety, effects (good and bad), and ability of denosumab to prevent breast cancer.
Who is this for?
Women aged 25 to 55 who do not have breast cancer and who have an inherited BRCA1 mutation.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Denosumab, by injection, every 6 months for up to 5 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for denosumab, by injection, every 6 months for up to 5 years</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Denosumab is a targeted therapy called a RANK ligand inhibitor. It is used to reduce the risk of bone fractures in people without cancer and to reduce new bone growth in people whose cancer has spread to their bones.</li> <li class="seamTextUnorderedListItem">Denosumab may also reduce the risk of developing breast cancer in women with an inherited (germline) BRCA1 mutation.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA 1</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04711109' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerpreventioninitiative.org/projects/prevention-of-breast-cancer-by-denosumab-in-women-carrying-a-brca1-or-brca2-mutation-brca-p-trial/' target='_blank'>Cancer Prevention Initiative: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a610023.html' target='_blank'>MedlinePlus: Denosumab</a> </li></ul>
3
NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City,UT
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT02694809
Duavee Hormone Therapy for Postmenopausal Women with DCIS
A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ Scientific Title
Purpose
To study the safety, effects (good and bad), and ability of a drug called conjugated estrogens/bazedoxifene (Duavee®) to reduce the risk of developing breast cancer.
Who is this for?
Postmenopausal women with newly diagnosed estrogen receptor positive (ER+) DCIS who are planning to receive surgery or have positive margins after surgery.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conjugated estrogens/bazedoxifene (Duavee®), by mouth, daily for 1 month</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for conjugated estrogens/bazedoxifene (Duavee®), by mouth, daily for 1 month</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conjugated estrogens/bazedoxifene (Duavee®) is a FDA approved hormone therapy used to treat symptoms of menopause such as hot flashes in women that do not have breast cancer.</li> <li class="seamTextUnorderedListItem">Because conjugated estrogens/bazedoxifene (Duavee®) is not approved in women with DCIS, its use in this study is experimental. </li> <li class="seamTextUnorderedListItem">Margins are the area around where DCIS was removed during surgery. A positive margin means DCIS cells were found in the margin after surgery.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02694809' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/conjugated-estrogens-and-bazedoxifene-oral-route/description/drg-20061326' target='_blank'>Mayo Clinic: Conjugated Estrogens/Bazedoxifene (Duavee®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/ductal-carcinoma-in-situ' target='_blank'>Breastcancer.org: DCIS</a> </li></ul>
4
NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ
VISITS: 1 visit
PHASE: NA
NCT ID: NCT06036875
Survey to Understand How Black and Hispanic Women Perceive Their Risk for Breast Cancer
CARE: Cancer Risk Perception and Women of Color Scientific Title
Purpose
To study how Black and Hispanic women understand their current and lifetime risk for breast cancer.
Who is this for?
Women, age 25-50 years, who are Black and/or Hispanic and who live in Arizona or Florida with no history of breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Survey, 1 time</li> <li class="seamTextUnorderedListItem">Interview (optional)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is examining the relationship between risk factors for breast cancer and a person's perceptions of those risk factors and if these relationships are different according to race and ethnicity.</li> <li class="seamTextUnorderedListItem">This study is also exploring how people reduce their risk for breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06036875' target='_blank'>ClinicalTrials.gov</a> </li></ul>
5
NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT05557877
Low-Dose Aspirin to Prevent Breast Cancer After Having a Baby
Targeted Prevention of Postpartum-Related Breast Cancer Scientific Title
Purpose
To study whether low-dose aspirin prevents breast cancer in women who have recently had a baby and who have benign (non-cancerous) breast disease.
Who is this for?
Pre-menopausal women, ages 18 to 45, who have had a baby in the last 5 years, have received a mammogram that suggested benign (non-cancerous) breast disease, and are planning to receive a biopsy. You must not be taking any medication to prevent breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">Blood tests</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low-dose aspirin, by mouth, daily</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low-dose aspirin, a non-steroidal anti-inflammatory drug, may reduce inflammation in blood and tissue which may prevent breast cancer after having a baby.</li> <li class="seamTextUnorderedListItem">Benign breast disease is non-cancerous breast disease.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05557877' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-minute-aspirins-role-in-preventing-and-stopping-the-spread-of-cancer/' target='_blank'>Mayo Clinic: Aspirin and Cancer Prevention</a> </li></ul>
6
NEAREST SITE: 1615 miles
Mayo Clinic
Rochester,MN
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT04570956
Tamoxifen Hormone Therapy for Women With Atypical Hyperplasia or LCIS
A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ Scientific Title
Purpose
To study changes in breast tissue after treatment with tamoxifen by mouth or gel.
Who is this for?
Women with atypical hyperplasia or lobular carcinoma in situ (LCIS).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for tamoxifen (Nolvadex®), by mouth, daily</li> <li class="seamTextUnorderedListItem">4-hydroxytamoxifen (TamGel®), gel rubbed on the breast, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for tamoxifen (Nolvadex®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Placebo for 4-hydroxytamoxifen (TamGel®), gel rubbed on the breast, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2 biopsies</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is a type of hormone therapy called a selective estrogen receptor modulator (SERM). SERMs work by blocking the activity of estrogen.</li> <li class="seamTextUnorderedListItem">4-hydroxytamoxifen (TamGel®) is a gel version of tamoxifen.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04570956' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/diseases-conditions/breast-cancer/in-depth/breast-cancer/art-20045353#:~:text=Tamoxifen%20is%20used%20to%20reduce,score%20is%20greater%20than%201.7%25.' target='_blank'>Mayo Clinic: Tamoxifen for Breast Cancer Prevention</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/tamoxifen' target='_blank'>Breastcancer.org: Tamoxifen (Nolvadex®)</a> </li></ul>
7
NEAREST SITE: 2054 miles
University of Michigan Rogel Cancer Center
Ann Arbor,MI
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT05700006
Effects of Hormone Therapy vs. No Hormone Therapy for Breast Cancer and Breast Cancer Prevention on Aging and the Microbiome
An Observational Study of Women With Breast Cancer Examining the Effect of Endocrine Therapy on Aging Scientific Title
Purpose
To study the effects of hormone therapy on biomarkers of aging and the microbiome.
Who is this for?
Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer or women at high risk of developing breast cancer. You must not have received treatment with an aromatase inhibitor for breast cancer or breast cancer prevention.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups depending on your situation: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Over 65 and Planning to Receive Hormone Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of anastrozole (Arimidex®), exemestane (Aromasin®), or letrozole (Femara®)</li> <li class="seamTextUnorderedListItem">3 stool samples, questionnaires, blood draws</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Over 65 and Not Planning to Receive Hormone Therapy (Control Group)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 stool samples, questionnaires, blood draws</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Under 65 and Planning to Receive Hormone Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of anastrozole (Arimidex®), exemestane (Aromasin®), or letrozole (Femara®)</li> <li class="seamTextUnorderedListItem">3 stool samples, questionnaires, blood draws</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microbiome is the collection of microorganisms (bacteria) living in your digestive tract.</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), exemestane (Aromasin®), and letrozole (Femara®) are types of hormone therapy called aromatase inhibitors. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05700006' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/arimidex' target='_blank'>Breastcancer.org: Anastrozole (Arimidex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/aromasin' target='_blank'>Breastcancer.org: Exemestane (Aromasin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/femara' target='_blank'>Breastcancer.org: Letrozole (Femara®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.insideprecisionmedicine.com/topics/oncology/breast-cancer/probiotic-bacteria-may-improve-efficacy-of-endocrine-targeted-therapies-for-breast-cancer/' target='_blank'>Inside Precision Medicine: Breast Cancer Treatments and the Microbiome</a> </li></ul>
8
NEAREST SITE: 2264 miles
UPMC Magee Womens Hospital
Pittsburgh,PA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT06218303
Vaccine to Prevent Breast Cancer for Women with ER+ DCIS
A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ Scientific Title
Purpose
To study the safety and ability of an experimental MUC1 peptide vaccine to prevent breast cancer in people with DCIS.
Who is this for?
Postmenopausal women with stage 0 (DCIS) estrogen receptor positive (ER+) breast cancer who are planning to receive surgery.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MUC1 peptide vaccine with Poly ICLC (Hiltonol®), by injection, 3-4 times within 3-9 months</li> <li class="seamTextUnorderedListItem">Aromatase inhibitor, by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitor, by mouth, daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Not all DCIS will progress to invasive breast cancer.</li> <li class="seamTextUnorderedListItem">Vaccines for DCIS may allow for less treatment. </li> <li class="seamTextUnorderedListItem">The MUC1 peptide vaccine is an experimental immunotherapy. The vaccine targets MUC1, which is a protein expressed by DCIS.</li> <li class="seamTextUnorderedListItem">Poly ICLC (Hiltonol®) is an immunotherapy that stimulates immune cells to go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®) are types of hormone therapy called aromatase inhibitors. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06218303' target='_blank'>ClinicalTrials.gov</a> </li></ul>
9
NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA
VISITS: At least 2 visits within 4 months
PHASE: NA
NCT ID: NCT06322888
Exercise to Reduce the Risk of Breast Cancer for Women With Dense Breasts
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D) Scientific Title
Purpose
To study how exercise might lower the risk of developing breast cancer by studying changes that occur in breast tissue and blood.
Who is this for?
Women 18-59 years old with dense breasts on a mammogram within the past year and exercise less than 1 hour every week. You must not have a history of breast cancer, be pregnant or breastfeeding, or be receiving hormonal birth control or hormone replacement therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, in person or virtual, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Exercise journal</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Biopsy, 2 times within 3 months</li> <li class="seamTextUnorderedListItem">Blood test, 2 times within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2 : Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy, 2 times within 3 months</li> <li class="seamTextUnorderedListItem">Blood test, 2 times within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> followed 3 months later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, 3 months (optional)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Greater physical activity is associated with a lower risk of breast cancer.</li> <li class="seamTextUnorderedListItem">Exercise may change markers in blood and breast tissue that play a role in breast cancer development.</li> <li class="seamTextUnorderedListItem">If you are in group 1, the exercise program includes aerobic and resistance training exercise with a certified exercise trainer.</li> <li class="seamTextUnorderedListItem">If you are in group 1, a FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to you. Hand weights will be returned at end of study.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06322888' target='_blank'>ClinicalTrials.gov</a> </li></ul>
10
RealRisks Online Program for Breast Cancer Risk Assessment
Integrating EHR and Patient-generated Health Data for Breast Cancer Risk Assessment and Decision Support in a Diverse Multiethnic Population Scientific Title
Purpose
To study how the RealRisks program promotes understanding of breast cancer risk and prevention and perceptions by users of their risk for breast cancer.
Who is this for?
Women, age 35-74 years old, at high risk for breast cancer but who have not been diagnosed with breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use of the RealRisks program, online</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RealRisks is a web-based patient-centered program designed to improve: 1) accurate understanding of breast cancer risk; 2) knowledge about drugs that could prevent breast cancer, and 3) making choices based on information. RealRisks includes audio and modules about breast cancer risk (including interactive games on risk communication) and drugs that could prevent breast cancer. </li> <li class="seamTextUnorderedListItem">Through RealRisks, study investigators will collect information on breast cancer risk factors to calculate a person's breast cancer risk score and also factors that influence decision-making about prevention. </li> <li class="seamTextUnorderedListItem">RealRisks generates an action plan for patients summarizing their personalized breast cancer risk and preference for prevention.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05810025' target='_blank'>ClinicalTrials.gov</a> </li></ul>
